IDH2 and glioma: Combination of histology with molecular genotyping of key markers: IDH, ATP-dependent helicase (ATRX), Lys-27-Met mutations in histone 3 (H3K27M), TP53 mutations, and 1p/19q chromosomal deletion improved the classification of gliomas and provided some predictors of patient clinical outcome [4,86].